May 2019

A CBD-based pharmaceutical drug in development is one more step closer to potential FDA approval. Earlier this week, London-based GW Pharmaceuticals plc, which operates in the United States as Greenwich Biosciences, wrapped up its New Drug Application for Epidiolex, a formulation of the cannabis compound cannabidiol (CBD) for the treatment of seizures associated with two […]

2018 will go down as a re­mark­able year for bio­phar­ma RD, and not just be­cause the in­dus­try post­ed an all-time record high in new drug/bi­o­log­ic ap­provals. Of­fi­cial­ly, there were 59 new mol­e­c­u­lar en­ti­ties — plus a string of bi­o­log­ics — ap­proved last year. Af­ter look­ing over the full list of each new drug ap­proved by CDER last […]

Advertisement At present, 31 countries in Europe have legalized medical cannabis, according to consultant Hanway Associates. But they’re all at different stages. Germany is already prescribing to patients, the UK has legalized but very few prescriptions have been written, and France is reviewing its regulation. EMMAC raised 17 million pounds ($22.4 million) in two private […]

Mavoglurant (AFQ056), a candidate for the treatment of fragile X syndrome (FXS), restored functionality in sensory networks but failed to do so in a cognition-related brain region in a mouse model of the disease, recent study shows. The research, “Inhibiting mGluR5 activity by AFQ056/Mavoglurant rescues circuit-specific functional connectivity in Fmr1 knockout mice” was published in […]

Here’s what Marijuana Moment found in our initial review. During a 2014 primary debate for the Republican US Senate nomination from Iowa, Whitaker sympathized with patients who benefit from marijuana ingredient cannabidiol (CBD). But he also voiced concerns about the disconnect between state legalization efforts and the enforcement of federal law under the administration of […]

While marijuana laws are cloudy at best, restraints on producing and selling hemp-derived cannabidiol (CBD), which is a non-psychoactive cannabis compound, are looser. CBD-infused products are trendy this year, with the extract popping up in everything from beverages to beauty products that promise to help with pain, anxiety, depression, and more. While Curt and Martha Van Inwegen of the […]

Advertisement Leeds is on the registry of Ohio physicians who can recommend but not prescribe medical marijuana for 21 qualifying medical conditions, such as epilepsy and chronic pain. Opioid use disorder is currently a qualifying condition in three other medical marijuana states: New York, Pennsylvania, and New Jersey. Ohio’s Medical Board is accepting petitions on […]

This year’s Indie Beauty Expo (IBE) held at Downtown Los Angeles is a prime example of its growth, with more than 180 brands and nearly 800 buyers, influencers, journalists and stockist. Co-founders Nader Naeymi-Rad and Jillian Wright expect press attendees to grow by 27.2 percent (from 1,179 to 1,500); Buyer attendance to grow 38.5 percent (from 1,805 to 2,500) across all of the shows […]

A cancer patient who accepted the disease would kill him saw his tumours shrink – by taking drops of cannabidiol (CBD) oil each day. The 81-year-old, who hasn’t been identified, repeatedly refused chemotherapy and other treatments to prolong his life. Instead, the ex-smoker, believed to be from the Stoke-on-Trent area, opted to take CBD oil […]

As the number of states legalizing cannabis as pain relief for cancers like lymphoma and other medicinal and recreational purposes increases, researchers published a report to help clinicians guide patient use. The report, “Contemporary Routes of Cannabis Consumption: A Primer for Clinicians,” was published in The Journal of the American Osteopathic Association. The two main […]

Zynerba Pharmaceuticals (NASDAQ:ZYNE) had its price objective upped by equities research analysts at Cantor Fitzgerald from $12.00 to $22.00 in a research note issued to investors on Friday, The Fly reports. The firm currently has an “overweight” rating on the stock. Cantor Fitzgerald’s price objective points to a potential upside of 78.14% from the company’s […]